Fusion protein that blocks BLyS and APRIL
Ph 2b primary endpoint early Q1 2023
Ph 3 primary endpoint
2026
Monoclonal antibody that neutralizes BK virus
Ph 2b or Ph 3 trial initiation 2023
Undisclosed
At Vera, we believe in changing standard of care for patients living with immunologic disease around the world. Collaborations are an essential part of this commitment, reach out to us at bd@veratx.com to discuss potential partnering opportunities.
